The House on Wednesday approved a $900 billion defense policy bill that would give U.S. troops a raise and codify much of ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective ...

We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from ...

The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align ...

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

FDA grants 1st approval under priority voucher program to Augmentin XR, expediting review and supporting U.S. antibiotic supply chain resilience.

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol ...

The FDA vaccine approval road map proposes longer trials and stricter evidence to improve vaccine safety and effectiveness oversight.

After weakening an endorsement for the hepatitis B vaccine, ACIP began debating the merits of the protocol used to inoculate ...